Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation

Bosch, 2002, The causal relation between human papillomavirus and cervical cancer, J. Clin. Pathol., 55, 244, 10.1136/jcp.55.4.244 zur Hausen, 2002, Papillomaviruses and cancer: from basic studies to clinical application, Nat. Rev. Cancer, 2, 342, 10.1038/nrc798 Walboomers, 1999, Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, J. Pathol., 189, 12, 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F Munoz, 2004, Against which human papillomavirus types shall we vaccinate and screen? The international perspective, Int. J. Cancer, 111, 278, 10.1002/ijc.20244 Munoz, 2003, Epidemiologic classification of human papillomavirus types associated with cervical cancer, N. Engl. J. Med., 348, 518, 10.1056/NEJMoa021641 Wheeler, 2007, Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing, Nat. Clin. Pract. Oncol., 4, 224, 10.1038/ncponc0770 Hildesheim, 2007, Effect of human papillomavirus 16/18L1 virus-like particle vaccine among young women with preexisting infection — a randomized trial, JAMA, 298, 743, 10.1001/jama.298.7.743 Tyring, 2000, Human papillomavirus infections: epidemiology, pathogenesis, and host immune response, J. Am. Acad. Dermatol., 43, S18, 10.1067/mjd.2000.107807 Tran, 2014, Control of HPV infection and related cancer through vaccination, Recent Results Cancer Res., 193, 149, 10.1007/978-3-642-38965-8_9 Ma, 2012, Emerging human papillomavirus vaccines, Expert Opin. Emerg. Drugs, 17, 469, 10.1517/14728214.2012.744393 Liu, 2012, Advances in peptide-based human papillomavirus therapeutic vaccines, Curr. Top. Med. Chem., 12, 1581, 10.2174/156802612802652402 Bolhassani, 2009, Different spectra of therapeutic vaccine development against HPV infections, Hum. Vaccin., 5, 671, 10.4161/hv.5.10.9370 Ressing, 2000, Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma, J. Immunother., 23, 255, 10.1097/00002371-200003000-00010 Muderspach, 2000, A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive, Clin. Cancer Res., 6, 3406 Toes, 1996, Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction, Proc. Natl. Acad. Sci. U. S. A., 93, 7855, 10.1073/pnas.93.15.7855 van der Burg, 2006, Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy, Adv. Drug Deliv. Rev., 58, 916, 10.1016/j.addr.2005.11.003 Bijker, 2007, Design and development of synthetic peptide vaccines: past, present and future, Expert Rev. Vaccines, 6, 591, 10.1586/14760584.6.4.591 Toes, 1996, Enhanced tumor outgrowth after peptide vaccination — functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors, J. Immunol., 156, 3911, 10.4049/jimmunol.156.10.3911 Bijker, 2007, CD8(+) CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity, J. Immunol., 179, 5033, 10.4049/jimmunol.179.8.5033 Zwaveling, 2002, Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides, J. Immunol., 169, 350, 10.4049/jimmunol.169.1.350 Rosalia, 2013, Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation, Eur. J. Immunol., 43, 2554, 10.1002/eji.201343324 Bijker, 2008, Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation, Eur. J. Immunol., 38, 1033, 10.1002/eji.200737995 Melief, 2008, Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines, Nat. Rev. Cancer, 8, 351, 10.1038/nrc2373 Welters, 2008, Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine, Clin. Cancer Res., 14, 178, 10.1158/1078-0432.CCR-07-1880 Kenter, 2008, Therapeutic HPV 16 vaccination with long E6 and E7 peptides shows immunological and clinical efficacy, Gynecol. Oncol., 108, S19-S19 Kenter, 2009, Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia, N. Engl. J. Med., 361, 1838, 10.1056/NEJMoa0810097 Aucouturier, 2002, Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines, Expert Rev. Vaccines, 1, 111, 10.1586/14760584.1.1.111 Aucouturier, 2006, The use of oil adjuvants in therapeutic vaccines, Vaccine, 24, S2-44-5 Silva, 2013, Immune system targeting by biodegradable nanoparticles for cancer vaccines, J. Control. Release, 168, 179, 10.1016/j.jconrel.2013.03.010 Speiser, 2005, Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909, J. Clin. Invest., 115, 739, 10.1172/JCI23373 Shibaki, 2002, Induction of skewed Th1/Th2 T-cell differentiation via subcutaneous immunization with Freund's adjuvant, Exp. Dermatol., 11, 126, 10.1034/j.1600-0625.2002.110204.x Akira, 2001, Toll-like receptors: critical proteins linking innate and acquired immunity, Nat. Immunol., 2, 675, 10.1038/90609 Melief, 2002, Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes, Immunol. Rev., 188, 177, 10.1034/j.1600-065X.2002.18816.x Salaun, 2007, Toll-like receptor 3 expressed by melanoma cells as a target for therapy?, Clin. Cancer Res., 13, 4565, 10.1158/1078-0432.CCR-07-0274 Steinhagen, 2011, TLR-based immune adjuvants, Vaccine, 29, 3341, 10.1016/j.vaccine.2010.08.002 Hafner, 2013, Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant, Adv. Drug Deliv. Rev., 64, 1386, 10.1016/j.addr.2013.05.013 Schlosser, 2008, TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses, Vaccine, 26, 1626, 10.1016/j.vaccine.2008.01.030 Hamdy, 2008, Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8(+) T cell-mediated anti-tumor immunity, Vaccine, 26, 5046, 10.1016/j.vaccine.2008.07.035 Wischke, 2009, Poly(I:C) coated PLGA microparticles induce dendritic cell maturation, Int. J. Pharm., 365, 61, 10.1016/j.ijpharm.2008.08.039 De Koker, 2011, Designing polymeric particles for antigen delivery, Chem. Soc. Rev., 40, 320, 10.1039/B914943K Toledo, 2001, A phase I clinical trial of a mufti-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers, Vaccine, 19, 4328, 10.1016/S0264-410X(01)00111-6 Gupta, 1993, Adjuvants — a balance between toxicity and adjuvanticity, Vaccine, 11, 293, 10.1016/0264-410X(93)90190-9 Leemhuis, 2006, Functionalized poly(alpha-hydroxy acid)s via ring-opening polymerization: toward hydrophilic polyesters with pendant hydroxyl groups, Macromolecules, 39, 3500, 10.1021/ma052128c Leemhuis, 2007, In vitro hydrolytic degradation of hydroxyl-functionalized poly(alpha-hydroxy acid)s, Biomacromolecules, 8, 2943, 10.1021/bm700476h Ghassemi, 2012, Controlled release of octreotide and assessment of peptide acylation from poly(D, l-lactide-co-hydroxymethyl glycolide) compared to plga microspheres, Pharm. Res., 29, 110, 10.1007/s11095-011-0517-3 Liu, 2012, The microclimate pH in poly(D, l-lactide-co-hydroxymethyl glycolide) microspheres during biodegradation, Biomaterials, 33, 7584, 10.1016/j.biomaterials.2012.06.013 Rahimian, 2015, Near-infrared labeled, ovalbumin loaded polymeric nanoparticles based on a hydrophilic polyester as model vaccine: in vivo tracking and evaluation of antigen-specific CD8+ T cell immune response, Biomaterials, 37, 469, 10.1016/j.biomaterials.2014.10.043 Kazazi-Hyseni, 2015, Biocompatibility of poly(d, l-lactic-co-hydroxymethyl glycolic acid) microspheres after subcutaneous and subcapsular renal injection, Int. J. Pharm., 10.1016/j.ijpharm.2014.12.014 Silva, 2013, Optimization of encapsulation of a synthetic long peptide in PLGA nanoparticles: low-burst release is crucial for efficient CD8(+) T cell activation, Eur. J. Pharm. Biopharm., 83, 338, 10.1016/j.ejpb.2012.11.006 Krishnamachari, 2011 Lin, 1996, Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen, Cancer Res., 56, 21 van Duikeren, 2012, Vaccine-induced effector-memory cd8(+) t cell responses predict therapeutic efficacy against tumors, J. Immunol., 189, 3397, 10.4049/jimmunol.1201540 Altman, 1996, Phenotypic analysis of antigen-specific T lymphocytes, Science, 274, 94, 10.1126/science.274.5284.94 Mundargi, 2008, Nano/micro technologies for delivering macromolecular therapeutics using poly(D, l-lactide-co-glycolide) and its derivatives, J. Control. Release, 125, 193, 10.1016/j.jconrel.2007.09.013 Couvreur, 1993, Nanoparticles and microparticles for the delivery of polypeptides and proteins, Adv. Drug Deliv. Rev., 10, 141, 10.1016/0169-409X(93)90046-7 Ma, 2012, PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses, Int. J. Nanomedicine, 7, 1475, 10.2147/IJN.S29506 Zhang, 2011, Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery, Biomaterials, 32, 3666, 10.1016/j.biomaterials.2011.01.067 Tinsley-Bown, 2000, Formulation of poly(d, l-lactic-co-glycolic acid) microparticles for rapid plasmid DNA delivery, J. Control. Release, 66, 229, 10.1016/S0168-3659(99)00275-8 Filipe, 2010, Critical evaluation of nanoparticle tracking analysis (nta) by nanosight for the measurement of nanoparticles and protein aggregates, Pharm. Res., 27, 796, 10.1007/s11095-010-0073-2 Wick, 2011, A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors, Vaccine, 29, 7857, 10.1016/j.vaccine.2011.07.090 Chen, 2013, Enhanced anti-tumor effects of HPV16E7(49–57)-based vaccine by combined immunization with poly(I:C) and oxygen-regulated protein 150, Cancer Epidemiol., 37, 172, 10.1016/j.canep.2012.10.005 Cui, 2006, Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model, Cancer Immunol. Immunother., 55, 1267, 10.1007/s00262-005-0114-6